Research
Hormonal
Newer emerging anti-obesity medications, specifically GLP-1/GIP/Glucagon receptor agonists (e.g., tirzepatide, retatrutide), demonstrate superior weight loss efficacy compared to older single-mechanism drugs.
Newer drugs like tirzepatide (Mounjaro/Mounjaro) can lead to nearly 21% weight loss in some patients, significantly higher than older drugs. These require weekly injections and are more expensive. Discuss with your doctor if the higher efficacy justifies the cost and injection burden for your specific health goals.
ModerateSupportsHIGH confidence
SURPASS-4, all three tirzepatide doses resulted in significantly greater HbA1c reduction than insulin glargine... Tirzepatide treatment also resulted in significantly more weight loss and less hypoglycemia.
Why this rating
Narrative review of trial data.
Source
A narrative review of approved and emerging anti-obesity medications
Semira Abdi Beshir et al. · Saudi Pharmaceutical Journal · 2023
DOI 10.1016/j.jsps.2023.101757
narrative_reviewCited 49×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →